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Quantifying the variation in the human plasma proteome is an essential prerequisite for disease-speciﬁc biomarker detection.
We report here on the longitudinal and individual variation in human plasma characterized by two-dimensional diﬀerence gel
electrophoresis (2-D DIGE) using plasma samples from eleven healthy subjects collected three times over a two week period.
Fixed-eﬀects modeling was used to remove dye and gel variability. Mixed-eﬀects modeling was then used to quantitate the sources
ofproteomicvariation.Thesubject-to-subjectvariationrepresentedthelargestvariancecomponent,whilethetime-within-subject
variation was comparable to the experimental variation found in a previous technical variability study where one human plasma
samplewasprocessedeighttimesinparallelandeachwasthenanalyzedby2-DDIGEintriplicate.Here,21proteinspotshadlarger
than 50% CV, suggesting that these proteins may not be appropriate as biomarkers and should be carefully scrutinized in future
studies. Seventy-eight protein spots showing diﬀerential protein levels between diﬀerent individuals or individual collections were
identiﬁed by mass spectrometry and further characterized using hierarchical clustering. The results present a ﬁrst step toward
understanding the complexity of longitudinal and individual variation in the human plasma proteome, and provide a baseline for
improved biomarker discovery.
1.Introduction
Mapping the human proteome presents a signiﬁcant sci-
entiﬁc challenge, partly because of the complexity of the
population and partly because of technological limitations
[1]. However, potential rewards in the diagnosis and treat-
ment of diseases make proteomic characterization of human
plasma a very worthwhile endeavor. The Human Proteome
Organization (HUPO) represents an international consor-
tium of academic and industrial partners whose common
goal is to foster collaboration and facilitate a better under-
standing of the human proteome. Recognizing the need for
reproducibility, and following in the footsteps of the more
matureﬁeldofgeneexpressionanalysis,proteomicstandards
are starting to emerge [2, 3]. The Human Plasma Proteome
(HPP)project[4]ofHUPO,whichspeciﬁcallytargetsplasma
proteins, has made considerable progress while highlighting
the complexity of plasma proteomics. For example, protein
identiﬁcation of the same specimen resulted in less than 50%
agreement when repeated multiple times [5, 6], reﬂecting
the challenges involved in biomarker discovery from human
plasma [7, 8] and underlining the need for improvements
in plasma proteomic characterization. Studies providing
prefractionation and other sample preparation aspects are
looking to improve this process [9–12].
A primary technological problem that needs to be
addressed is the quantiﬁcation of the experimental vari-
ation on a given proteomic platform. Next, the baseline
variation within individuals over time and the variation
between multiple individuals also need to be quantitated.
Searching for disease-speciﬁc biomarkers makes sense only
after these two steps are addressed. Our recent study,
referred to as the Technical Variation Study (TVS) [13]
throughout the manuscript, addressed the ﬁrst question for
two-dimensional diﬀerence gel electrophoresis (2-D DIGE)
experiments by processing one human plasma sample eight2 Journal of Biomedicine and Biotechnology
times and analyzing each of the resulting eight technical
replicates in triplicate on twelve gels [13–16]. The present
study is a follow-up to the TVS, whereby plasma samples
from eleven healthy volunteer subjects, taken at three time
points separated by two weeks, were analyzed in triplicate on
50 gels.
The goal of this study was to assess longitudinal and
individualvariationinhumanplasmaandtocompareresults
to the experimental variation detected in the previously
reported TVS [13]. While diﬀerences were detected in
the plasma proteome within individuals over time, our
analyses indicate that individual variation contributes the
largest observed proteomic variability. Further, our results
demonstrate that gender-related proteomic diﬀerences can
be detected by 2-D DIGE and should also be considered
in biomarker discovery. Overall, this work represents a
ﬁrst step in quantitating the variability in human plasma
by addressing the individual and longitudinal proteomic
variation in human plasma.
2.MaterialsandMethods
2.1. Sample Collection. Blood samples were collected from
eleven healthy volunteers (ﬁve males, six females) at three
time points separated by two weeks, with informed consent
under Institutional Review Board approval from Lawrence
Livermore National Laboratory. To minimize the eﬀect of
daily variations within an individual, the samples from a
given subject were taken at approximately the same time,
within a thirty-minute window, in the morning for each
time point. Other variables were not controlled for in order
to better mimic the variability in typical human plasma
samples (age, fasting, illness, medication, etc.). To better
examine the longitudinal variation and minimize the chance
of an individual providing samples while experiencing an
underlying condition such as a cold, two weeks between
sample collection were chosen. Each individual was assigned
an identiﬁcation number to blind the samples and ease the
experimental design.
2.2. Top-6 High-Abundance Protein Depletion and Sample
Preparation. To increase the resolution of the 2-D DIGE
technique, the six most abundant plasma proteins were
depleted using aﬃnity chromatography, as previously
reported [12]. The sample cleanup and protein assay was
performed as described previously [12, 13, 17, 18].
2.3. 2-D DIGE and Gel Imaging. The 33 top-6-depleted
plasma samples from the 11 individuals were analyzed in
triplicate in a 50-gel 2-D DIGE experiment [13–16] (see
Table 1 in Supplementary Material available online at doi:
10.1155/2010/258494). Each gel contained three samples,
one internal pooled standard and two experimental samples.
The internal pooled standard consists of an equal amount
of each of the 33 samples and was labeled with the Cy2
dye (GE Healthcare). Each experimental sample was dye-
swappedandlabeledwithboththeCy3andtheCy5dyes(GE
Healthcare) in the experimental design to mitigate the eﬀect
of potential dye-speciﬁc variations [19]. Samples from
individuals obtained at diﬀerent times were compared on
some gels, while samples from two diﬀerent individuals were
compared on other gels. Gels were run randomly in batches
of twelve in order to minimize batch-to-batch variability.
Supplementary Table 1 shows the complete experimental
design. Labeling ﬁrst dimension (pI) separation, second
dimension (mw) separation, and gel imaging was performed
as described previously [13]. Mass spectrometry was carried
out as previously described [20].
2.4. Data Analysis. The DeCyder Diﬀerential Analysis Soft-
ware v5.01 (GE Healthcare) was used for quantitating
diﬀerential abundance of proteins. The Diﬀerential In-gel
Analysis (DIA) module was used to determine the optimal
spot detection settings. Images were loaded into the Batch
Processor module with the estimated number of spots set to
2,500. The master gel was assigned automatically to the gel
with the most spots detected. Each sample was grouped for
analysis in the Biological Variation Analysis (BVA) module.
During batch processing, the Cy2 channel from each gel
was used for normalization of the spot intensities and for
automated matching between gels. For each spot on each
gel, the software reported the standardized abundance (SA)
as the ratio of the volume in the Cy3 (or Cy5) sample
to the volume of the pooled standard sample labeled with
Cy2, where the volumes were normalized across the gels.
Standardized log abundance (SLA), deﬁned as log10(SA),
was used in quantifying diﬀerential expression. Fold change
between groups was calculated as the ratio of the average SA
in the two groups. If R denotes that ratio, the fold change F
was deﬁned as F = R if R  1a n dF =− 1/R otherwise. A k-
fold expression increase/decrease corresponded to a +k/ − k
value of F.
Using DeCyder, all possible pairwise comparisons were
made between the 33 groups deﬁned by the eleven subjects
at the three times. Within the BVA module each comparison
was ﬁltered to ﬁnd the spots having (a) P-value ≤.05 and
(b) greater than 1.5-fold change in expression between
the groups. The analysis was converted into DeCyder 2D
(v6.5), and the Extended Data Analysis (EDA) module
(GE Healthcare) was used to perform expression pattern
clustering [21–26]. Data from the TVS were integrated into
theanalysis,pooledstandardswerenormalizedandprincipal
component analysis was conducted [27–30] on the spots that
were successfully matched on >75% of the gels from the TVS
and the present study [13].
Spot characteristicscalculatedbyDeCyderwereexported
for further statistical processing into the R statistical
computing environment [19]( http://www.r-project.org/).
Summary statistics for the spot matching across the gels
were calculated. The high-quality spots, deﬁned as the spots
matched onat least75% of the gels,weresubjected tofurther
analysis. Spotwise standard deviations (SDs) of the SLA
values and coeﬃcients of variations (CVs) of the SA values
were calculated, ﬁrst by using all the data at a given spot to
obtain one SD and one CV for that spot, then by performing
the same calculations separately for the eleven subjects, thusJournal of Biomedicine and Biotechnology 3
obtainingelevenSDandCVvaluesforeachspot.Theformer
method estimated the protein expression variation among
all subjects and time points, while the latter addressed the
variation within individuals through time. The results were
compared to the spotwise SD and CV values obtained from
the TVS [13].
Toquantitatetherelativecontributionofthecomponents
of variation, mixed-eﬀects statistical modeling [31]w a s
performed. Let yijk denote the SLA at spot i on gel j
measured with dye k, with i = 1,...,I,w h e r eI represents
the number of spots matched on 75% of the gels, j =
1,...,50, and k = 1,2. In addition, let l = 1,...,11 and
m = 1,2,3 indicate the subject and time indices, respectively.
Let g = 1,2 indicate male and female genders, respectively.
The assumed model was of the form
yijklm = μ+αj +βk +

αβ

jk +γig +ail +bil(m) +eijklm,( 1 )
where μ is the overall mean, αj denote the coeﬃcients for
the ﬁxed gel eﬀects, βk the coeﬃcients for the ﬁxed dye
eﬀects, (αβ)jk the coeﬃcients for the gel-dye interactions,
γig the coeﬃcient for the ﬁxed gender eﬀect at spot i,a n d
ail, bil(m),a n deijklm the random eﬀects components for
subject (individual), time (longitudinal), and error at spot
i, independent and normally distributed [32]w i t hm e a n
zero and variance σ2
si, σ2
ti,a n dσ2
ei,r e s p e c t i v e l y .T h eg e n d e r ,
subject, and time subscripts in (1) are redundant, as for
any given j and k, the identity of the sample, including the
subject, gender and time, was known. However, we included
them for the clarity of the model description. Since the
gel and dye factors were balanced with respect to the spots
(the ﬁrst four terms in the model were common to all
spots), (1) was ﬁt in two stages, with results equivalent to,
and computationally more eﬃcient than, the full one-stage
solution in (1) repeated at each spot. Similar methods have
been established for microarrays [33]. In the ﬁrst stage, the
data from all I spots were used to estimate the global dye
and gel eﬀects; that is, only the ﬁrst four terms in (1)p l u s
errorwereincludedinthemodel.Inthesecondstage,thelast
four terms in (1) were ﬁt to the residuals from the ﬁrst stage,
one spot at a time. In essence, this ﬁrst stage amounted to a
normalizationstep,wherebytheﬁxeddyeandgeleﬀectswere
estimated and removed by pooling the information across
all the spots. In the second stage, a ﬁxed gender eﬀect and
random variance components of subject, time, and error
were estimated separately at each spot. Thus, at spot i, the
total variance σ2
yi was separated into its random components
as σ2
yi = σ2
si +σ2
ti +σ2
ei.
The eﬀect of additional statistical normalizations of
the SLA on the variance component estimates and on the
diﬀerentially expressed spots was investigated. The SLA
values obtained from DeCyder were further normalized
by statistical methods that corrected for potential dye
biases within gels and range diﬀerences among the gels as
previously described [34].
The spots that were determined to be of diﬀerential
abundance (>1.5-fold diﬀerence with P-value <.05) were
excisedfromthepickgelandidentiﬁedbymassspectrometry
as previously reported [12, 18, 20]. Identiﬁed spots were
selected in DeCyder for additional expression pattern clus-
tering.
3. Results and Discussion
3.1. Experimental Design. The experimental design is shown
in Supplementary Table 1 and Supplementary Figure 1.
Rather than randomly pairing the samples on the gels, the
design was selected to minimize the experimental variation
among the samples whose comparison was of most interest.
By placing the samples from a subject across diﬀerent
time points on the same gel, gel-related variations for
intrasubject comparisons were minimized. Essentially, our
design was based on the requirements that (1) each of the
33 samples has three replicates and (2) comparisons of the
samples from the same subject were of more interest than
comparisons of diﬀerent subjects across time points. This
led to an experimental design that contained 22 gels used for
comparing the same individual at diﬀerent time points and
28 gels to compare two individuals at diﬀerent time points.
In addition, the use of dye swapping and triplicates also
contributed to overall quality of the data. Our results suggest
that gender variability may also be present. As individual and
longitudinal variability was our main objective, we did not
attempt to control for gender diﬀerences. We selected both
males and females for our study to get a more appropriate
human sample set. Future work looking at human proteome
variability should account for gender-speciﬁc variability in
the design of the experiment.
3.2. Spot Matching. Landmarks were placed manually on
eachgeltoassistinthespotmatchingacrossthegels.Spotsof
interest identiﬁed through the analyses were veriﬁed to have
the three-dimensional proﬁle characteristics of a protein
spot. Those spots with volumes close to background level
and dust particles with very large slopes and small areas were
eliminated. The total number of protein spots detected on
the master gel was 2556. Three hundred and ninety seven
(15%) spots were matched on at least 37 gels, and 1215
(46%) spots were matched on at least 25 gels. The following
statistical analyses were restricted to the 397 high-quality
spots matched on 75% of the gels. These high-quality spots
werechosentofocusonspotsthatdidnotrequirewarpingor
imputing of any missing data. Future data analysis may help
determine if warping and data imputation can expand high-
quality gel proteomic data. The latest version of DeCyder
contains the ability to warp gels to potentially add missing
data. These additions may provide additional spots that can
bestudiedashigh-quality,butthistypeofdatamanipulation
may also create skewed expression values, as the results
depend on the type of postrun imputation model that is
utilized [35].
Our previous study with technical replicates of one
humanplasmasample[13]had42%ofthespotsmatchedon
8of12gels.Theadditionofbiologicalsamplesfromdiﬀerent
subjectsatvaryingtimepointsaddedtothecomplexityofthe
current dataset and reduced the matching accuracy. While
most of the decrease in the matching accuracy is expected to4 Journal of Biomedicine and Biotechnology
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Figure 1: The spatial distribution of proteins spots (yellow dots)
detected in human plasma by 2-D DIGE. Identiﬁed proteins (blue
dots) and those showing diﬀerences between the theoretical and
observed molecular weights (numbered red dots) are highlighted.
stem from the biological complexity of the experiment, part
of it may be attributed to the larger number of gels, which
inevitably increases the expected experimental variation. A
study of ﬁve commercial software programs showed that an
average of only 3% of the total analysis time was automated
as opposed to manual, and as the number of gels increased,
the percentage of automatically generated correct matches
was dramatically reduced [36]. Taken together, these studies
suggest that improved spot detection and matching software
and algorithms are needed to increase the quality of spot
matching. One such study was accomplished that created
algorithms to improve spot matching with an integrated
approach using hierarchical-based and optimization-based
methods [37].
3.3. Diﬀerential Expression and Protein Identiﬁcations. The
pairwise comparisons among the 33 samples identiﬁed over
1400 spots with P-value <.05 and fold-change > 1.5. Down
selection using manual inspection eliminated most of these
spots (due to three-dimensional proﬁle characteristics not
representative of protein or because of insuﬃcient represen-
tation of the spot on enough gels) resulting in 427 spots
of further interest. The majority of the spots that did not
pass manual veriﬁcation were similar to background levels,
lacking visual characteristics of protein spots. The sensitive
detection parameters used in this study, while allowing for
the detection of low abundance proteins, results in increased
detection of artifacts that require manual veriﬁcation.
Of the 427 spots with diﬀerential abundance, those
exhibiting the greatest diﬀerences in abundance levels were
further characterized, and 78 proteins spots were identiﬁed
by mass spectrometry. The identiﬁed proteins are listed
in Table 2, along with the theoretical pI and molecular
weight calculated from the full-length amino acid sequence
of each protein. Figure 1 depicts the spatial distribution
of the protein spots detected in human plasma by 2-
DD I G E .I d e n t i ﬁ e dp r o t e i n sa r ed e n o t e db yb l u ed o t s .
Sixteen proteins (red dots) were found to have diﬀerences
between the theoretical and observed molecular weights.
The discrepancies are potentially due to posttranslational
modiﬁcations or experimental processing; however, since all
samples were treated identically, posttranslational modiﬁca-
tion is more likely. For example, spots 2189 and 2184, both
identiﬁed as complement component C4A, were found to
be statistically signiﬁcant with at least a 1.5-fold diﬀerence
between individuals. Complement component C4A has a
theoretical molecular weight of 192.8kDa; yet the protein
spots identiﬁed indicate an approximate 32kDa fragment.
Since only C-terminal peptides were detected by mass
spectrometry, the protein spot likely corresponds to the
active Complement C4c fragment (mw = 33kDa), which is
a known cleavage product of Complement C4A [38, 39].
Variability in the amount of Complement C4c fragment
between individuals could be a reﬂection of immune status,
which may be a considerable variable when comparing
human clinical subjects.
3.4. Spotwise Variation. The distribution of the SLA was
consistentacrossthegels.Thespot-wiseSDvaluesoftheSLA
for the 397 high-quality spots, when considering all samples,
ranged from 0.04 to 0.53, with a median of 0.10. When
broken down separately by subject, the range was 0.0002 to
0.50, with 0.06 as the median, reﬂecting the lower variation
of time-within-subjects than variation between the diﬀerent
subjects. Both sets of values represented an increase from
the spot-wise SDs observed among technical replicates of
the same human plasma sample [13], where the maximum
was 0.20 and the median 0.04. In the previous TVS work
[13], the CV values of the SA had a median of 10% and a
maximum of 42%. Here, the range of the spot-wise CVs was
10% to 93%, with a median CV of 23%. The higher CVs of
the present study reﬂect the additional complexity due to the
heterogeneity of the samples from multiple human subjects.
These results are comparable to the recently reported 6%
(min), 108% (max), and 19% (median) CVs found in a 2-D
DIGEstudyofnormalliversamplesfromtenhumansubjects
[40]. Here, about 90% of the spots had less than 40% CV,
and only 21 spots (5% of the 397 high-quality spots) had
higherthan50%CV.Thespotsarelikelynotgoodbiomarker
candidates due to their high individual or longitudinal
variability. These spots showing relatively high variation may
correspond to a single isoform of individual proteins and
do not represent all isoforms of any given protein. Notably,
several of the proteins identiﬁed (Albumin, Transferrin,
Haptoglobin, IgG, and IgA) are proteins removed by the
Top-6 depletion process [12], which was subsequently found
to result in variability when processing multiple samples
in series. In future studies, column equilibration steps are
recommendedbetweensamplestoreducethisvariabilityand
ensure more complete depletion of high-abundant proteins.
In summary, the majority of the spots had small enough
CV to indicate that the corresponding protein expressions
were relatively constant across individuals, and thus could be
potentially used as biomarkers. The minimum, maximum,
and median CVs, when calculated separately for the subjectsJournal of Biomedicine and Biotechnology 5
Table 1: Frequency distribution of the variance component estimates.
% contribution to total variance Subject Time in subject Error
(a) (b) (a) (b) (a) (b)
0–10 6.31 6.31 63.89 63.89 6.57 6.57
10–20 9.34 15.66 17.68 81.57 17.17 23.74
20–30 12.89 28.50 7.83 89.39 16.67 40.40
30–40 14.14 42.68 4.29 93.69 9.34 49.75
40–50 13.63 56.31 2.27 95.96 10.86 60.61
50–60 11.36 67.68 3.03 98.99 11.87 72.47
60–70 11.36 79.04 0.51 99.49 10.37 82.83
70–80 11.61 90.66 0.50 100.00 8.08 90.91
80–90 7.83 98.48 4.80 95.71
90–100 1.51 100.00 4.29 100.00
The components of subject (σs), time-within-subject (σt), and random error (σe) are shown separately as (a) the percentage of spots and (b) the cumulative
percentage of spots with contribution to the total variance indicated in the ﬁrst column.
were 0.05%, 131%, and 14%, respectively. Over 95% of the
CVs were below 35%, indicating that for most subjects, the
variation over the three timepoints was comparable to the
experimental variation in the previously published TVS data
[13].
3.5. Statistical Normalization, Gel and Dye Eﬀect Removal,
and Variance Decomposition. The SLA values were further
normalized as explained in the methods. The eﬀect of the
normalization on the results is addressed as appropriate in
thefollowingsections.TheF-testsfortheanalysisofvariance
calculations corresponding to (1) indicated signiﬁcant gel
(P-value < 2.2e−16), dye (P-value < 3.2e−16), and gel-
dye interaction (P-value < 2.2e−16) eﬀects. The residual
diagnostic plots did not reveal major departures from the
assumptions, thus indicating the validity of the model.
SimilaranalysesusingthenormalizedSLAresultedinslightly
higher P-values (gel eﬀect P-value < 2.2e−16, dye eﬀect P-
value.003, gel-dye interaction P-value < 3.0e−09) but were
consistent with the conclusions based on the calculations
using the SLA.
The standard deviations corresponding to the random
variance component estimates from the mixed-eﬀects model
(Figure 2) show the relative contribution of the three com-
ponents at each of the spots matched on 75% of the gels.
Overall, the time-within-subject component was found to
have the smallest contribution to the total variance, while
subject-related variation had the highest. The corresponding
frequency distributions of the three variance components
(Table 1)conﬁrmthatformostspots(89%)thecontribution
of the time component was less than 30% of the total
variance. Only 5% of the spots had 70% to 80% of their
variation explained by the time component, and no spot
had the time component greater than 80% of the total
variance. For 21% of the spots, the contribution of the
subjectcomponentcomprisedover70%ofthetotalvariance.
For about 44% of the spots, the contribution of the subject
component represented over 50% of the total variation.
To further elucidate the contributing factors involved in
spot variance, we performed a meta-analysis on these data.
The 397 spots matched on 75% of the gels
Error
Time in subject
Subject
0
0.2
0.4
0.6
S
D
Figure 2: The subject (σs), time-within-subject (σt), and random
error (σe) variance component estimates (on SD scale) for the 397
protein spots matched on at least 75% of the gels, ordered by the
magnitude of the subject component.
Essentially, all the variances for the 397 high-quality spots
were summed and the total variance that could be explained
by the sum of the spot-wise subject, time within-subject, and
error components was determined, respectively. A pooled
estimate of the variance components was obtained by taking
the average of the corresponding variance components over
the spots. When aggregating the total variance over all the
spots matched on at least 75% of the gels, the sum of the
subject components explained 59% of the total variation and
the sum of the time-within-subject components explained
12% of the total variation. The average subject variance
component across the spots was 0.0097 (corresponding to σs
= 0.098 on the Sd scale), and the average time-within-subject
variance component was 0.0019 (σt = 0.044).
3.6. Multivariate Analysis of Expression Patterns. The EDA
module of DeCyder 2D was used to visually display the6 Journal of Biomedicine and Biotechnology
Table 2: Variable proteins identiﬁed from human plasma.
Protein Number Protein Identity Accession Number mwa pIa Gene
614a clusterin IPI00400826 57.8 6.25 CLU
614b alpha-2-macroglobulin precursor IPI00478003 163.3 6 A2M
835a alpha-2-macroglobulin precursor IPI00478003 163.3 6 A2M
835b Complement C3 precursor IPI00783987 187.1 6.02 C3
849 Plasminogen IPI00019580 90.6 7.04 PLG
856 Plasminogen IPI00019580 90.6 7.04 PLG
881a complement factor B preproprotein IPI00019591 85.5 6.67 CFB
881b complement protein C7 precursor IPI00296608 93.5 6.09 C7
881c Complement C3 precursor IPI00783987 187.1 6.02 C3
884 Plasminogen IPI00019580 90.6 7.04 PLG
893 complement factor B preproprotein IPI00019591 85.5 6.67 CFB
899a complement factor B preproprotein IPI00019591 85.5 6.67 CFB
899b complement protein C7 precursor IPI00296608 93.5 6.09 C7
899c Complement C3 precursor IPI00783987 187.1 6.02 C3
910a ﬁbrinogen gamma IPI00219713 49.5 5.7 FGG
910b complement factor B preproprotein IPI00019591 85.5 6.67 CFB
956a complement component 1, r subcomponent IPI00296165 80.2 5.89 C1R
956b complement component C4A IPI00032258 192.8 6.66 C4A
963 complement component 1, r subcomponent IPI00296165 80.2 5.89 C1R
1002 complement component 1,s subcomponent IPI00017696 76.7 4.86 C1S
1004a gelsolin IPI00646773 80.6 5.58 GSN
1004b complement component 2 IPI00303963 83.3 7.23 C2
1004c complement factor B preproprotein IPI00019591 85.5 6.67 CFB
1004d complement protein C7 precursor IPI00296608 93.5 6.09 C7
1004e alpha-2-macroglobulin precursor IPI00478003 163.3 6 A2M
1004f Complement C3 precursor IPI00783987 187.1 6.02 C3
1004g complement component C4A IPI00032258 192.8 6.66 C4A
1027 transferrin IPI00022463 77 6.81 TF
1110 IGHM protein IPI00828205 65.3 8.1 IGHM
1113a IGHM protein IPI00828205 65.3 8.1 IGHM
1113b transferrin IPI00022463 77 6.81 TF
1128a IGHM protein IPI00828205 65.3 8.1 IGHM
1128b transferrin IPI00022463 77 6.81 TF
1129a histidine-rich glycoprotein precursor IPI00022371 59.6 7.09 HRG
1129b coagulation factor XII precursor IPI00019581 67.5 7.94 F12
1129c transferrin IPI00022463 77 6.81 TF
1142a histidine-rich glycoprotein precursor IPI00022371 59.6 7.09 HRG
1142b transferrin IPI00022463 77 6.81 TF
1156 transferrin IPI00022463 77 6.81 TF
1185 transferrin IPI00022463 77 6.81 TF
1254 hemopexin precursor IPI00022488 51.5 6.57 HPX
1263a histidine-rich glycoprotein precursor IPI00022371 59.6 7.09 HRG
1263b Complement C3 precursor IPI00783987 187.1 6.02 C3
1276a hemopexin precursor IPI00022488 51.5 6.57 HPX
1276b Heparin cofactor II precursor IPI00292950 57.1 6.41 HCF2
1276c peptidoglycan recognition protein L precursor IPI00163207 62.2 7.25 PGLYRP
1382 kininogen IPI00215894 47.9 6.29 KNG
1394 albumin IPI00745872 69.1 5.85 ALB
1456 alpha-1-antichymotrypsin precursor IPI00550991 45.5 5.32 AACT
1471a immunoglobulin alpha-1 heavy chain IPI00166866 37.6 6.06 IGHA1
1471b kininogen IPI00215894 47.9 6.29 KNGJournal of Biomedicine and Biotechnology 7
Table 2: Continued.
Protein Number Protein Identity Accession Number mwa pIa Gene
1471c antithrombin III IPI00032179 52.6 6.32 AT3
1525 Vitronectin precursor IPI00298971 54.3 5.55 VTN
1526a kininogen IPI00215894 47.9 6.29 KNG
1526b Angiotensinogen IPI00032220 53.2 5.78 AGT
1555 Vitronectin precursor IPI00298971 54.3 5.55 VTN
1558 immunoglobulin alpha-2 heavy chain IPI00641229 36.4 5.71 IGH
1568a kininogen IPI00215894 47.9 6.29 KNG
1568b antithrombin III IPI00032179 52.6 6.32 AT3
1568c Angiotensinogen IPI00032220 53.2 5.78 AGT
1577 Alpha-2-HS-glycoprotein IPI00022431 39.3 5.43 AHSG
1589a immunoglobulin alpha-1 heavy chain IPI00166866 37.6 6.06 IGHA1
1589b apolipoprotein H precursor IPI00298828 38.3 8.34 APOH
1589c prepro-plasma carboxypeptidase B IPI00329775 48.4 7.61 pCPB
1589d ﬁbrinogen beta chain IPI00298497 55.9 8.54 FGB
1589e alpha-2-macroglobulin precursor IPI00478003 163.3 6 A2M
1616a apolipoprotein H precursor IPI00298828 38.3 8.34 APOH
1616b ﬁbrinogen beta chain IPI00298497 55.9 8.54 FGB
1626 Alpha-2-HS-glycoprotein IPI00022431 39.3 5.43 AHSG
1648 ﬁbrinogen beta chain IPI00298497 55.9 8.54 FGB
1650a apolipoprotein D IPI00006662 28 5.14 APOD
1650b Alpha-2-HS-glycoprotein IPI00022431 39.3 5.43 AHSG
1650c alpha-1-antichymotrypsin precursor IPI00550991 45.5 5.32 AACT
1650d ﬁbrinogen gamma IPI00219713 49.5 5.7 FGG
1652 Alpha-2-HS-glycoprotein IPI00022431 39.3 5.43 AHSG
1725 vitamin D-binding protein precursor IPI00742696 52.9 5.32 GC
1731 vitamin D-binding protein precursor IPI00742696 52.9 5.32 GC
1740 vitamin D-binding protein precursor IPI00742696 52.9 5.32 GC
1741 vitamin D-binding protein precursor IPI00742696 52.9 5.32 GC
1744 vitamin D-binding protein precursor IPI00742696 52.9 5.32 GC
1749 vitamin D-binding protein precursor IPI00742696 52.9 5.32 GC
1752 vitamin D-binding protein precursor IPI00742696 52.9 5.32 GC
1843a pigment epithelial-diﬀerentiating factor IPI00006114 46.3 5.84 PEDF
1843b ﬁbrinogen gamma IPI00219713 49.5 5.7 FGG
1898 vitamin D-binding protein precursor IPI00742696 52.9 5.32 GC
1911a serum paraoxonase IPI00218732 37.8 4.96 PON
1911b ﬁbrinogen gamma IPI00219713 49.5 5.7 FGG
1911c Complement C3 precursor IPI00783987 187.1 6.02 C3
1918 serum paraoxonase IPI00218732 37.8 4.96 PON
1925a serum paraoxonase IPI00218732 37.8 4.96 PON
1925b ﬁbrinogen gamma IPI00219713 49.5 5.7 FGG
1985a serum paraoxonase IPI00218732 37.8 4.96 PON
1985b haptoglobin IPI00641737 45.2 6.13 HP
1986a apolipoprotein A-IV precursor IPI00304273 43.4 5.22 APOA4
1986b haptoglobin IPI00641737 45.2 6.13 HP
1986c serum paraoxonase IPI00218732 37.8 4.96 PON
1998 apolipoprotein A-IV precursor IPI00304273 43.4 5.22 APOA4
2008 apolipoprotein A-IV precursor IPI00304273 43.4 5.22 APOA4
2029 alpha-2-glycoprotein 1 IPI00166729 34.3 5.71 AZGP1
2030a apolipoprotein A-IV precursor IPI00304273 43.4 5.22 APOA4
2030b haptoglobin IPI00641737 45.2 6.13 HP
2065a haptoglobin IPI00641737 45.2 6.13 HP8 Journal of Biomedicine and Biotechnology
Table 2: Continued.
Protein Number Protein Identity Accession Number mwa pIa Gene
2065b Complement factor I IPI00291867 65.8 7.72 CFI
2095a alpha-1-antichymotrypsin precursor IPI00550991 45.5 5.32 AACT
2095b clusterin IPI00400826 57.8 6.25 CLU
2130a Proapolipoprotein IPI00021841 29 5.45 APOA1
2130b Complement factor I IPI00291867 65.8 7.72 CFI
2137 clusterin IPI00400826 57.8 6.25 CLU
2184 complement component C4A IPI00032258 192.8 6.66 C4A
2189 complement component C4A IPI00032258 192.8 6.66 C4A
2191 transthyretin IPI00022432 15.9 5.5 TTR
2236 immunoglobulin kappa light chain IPI00784070 26 8.16 IGKC
2259 amyloid P component IPI00022391 25.4 6.1 APCS
2260 amyloid P component IPI00022391 25.4 6.1 APCS
2272a lambda-chain precursor IPI00154742 24.7 7.54 IGL
2272b immunoglobulin kappa light chain IPI00784070 26 8.16 IGKC
2284 immunoglobulin kappa light chain IPI00784070 26 8.16 IGKC
2314 Proapolipoprotein IPI00021841 29 5.45 APOA1
2325 Proapolipoprotein IPI00021841 29 5.45 APOA1
2326 Proapolipoprotein IPI00021841 29 5.45 APOA1
2338 Proapolipoprotein IPI00021841 29 5.45 APOA1
2346 plasma glutathione peroxidase IPI00026199 16.7 8.93 GPx-P
2415 haptoglobin IPI00641737 45.2 6.13 HP
2468 transthyretin IPI00022432 15.9 5.5 TTR
2520 haptoglobin IPI00641737 45.2 6.13 HP
aTheoretical molecular weight (mw) in kDa and isoelectric point (pI)v a l u e s .
results of the current study and the previous TVS study
[13]( Figure 3). The multivariate expression proﬁles of the
samples across 328 spots that were matched on >75% of
the spot maps from both studies were transformed into the
principal component basis and the projection of the samples
ontotheﬁrsttwoprincipalcomponentsdisplayed(Figure 3).
The tight scatter of the samples from the TVS (encircled
in black) indicates the small magnitude of the experimental
variability when analyzing technical replicates of the same
human sample. The magnitude of the longitudinal variation
exceeded the technical variation, as evidenced by the larger
scatter of the sample points of a given subject at the
diﬀerent time points. For example, the two red and green
ellipses (Figure 3) highlight the longitudinal variation for
subjects 1 and 11, respectively. The diﬀerential scattering
of the samples, from the subjects into varying regions of
the principal components plot, indicates that the subject-to-
subject variation exceeded the longitudinal variation within
subjects.
Hierarchical clustering was used to group the 33 samples
based on the similarity of their protein expression proﬁles
along the 397 high-quality spots that were matched on >75%
of the gels (Figure 4). Clustering was performed in on the
proteins and experimental samples, using Euclidean distance
and average linkage to deﬁne similarity. For all subjects,
the ﬁrst clustering step placed the three samples of the
given subject into one cluster. Samples of the same subject
collected at the three time points were most similar to each
2 1 0 −1 −2
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Figure 3: Principal component analysis of the 33 samples from
the present study and the 8 replicates from the previous Technical
Variation Study (TVS) [9], color-coded according to the legend,
projected onto the ﬁrst two principal components. Ellipses high-
lighting subjects 1 (red), 11 (green), and the TVS (black) are added
for illustrative purposes only.Journal of Biomedicine and Biotechnology 9
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Figure 4: Hierarchical clustering of the 33 samples (y-axis) based
on the abundance of the 397 high-quality protein spots on the x-
axis, using Euclidean distance and average linkage. The samples are
in SubjectNumberTime format, where SubjectNumber ranges from
01 to 11, and the Time values {x, y,a n dz } correspond to {T1,
T2,a n dT3}. The intensities range from −1.5-fold change (bright
green) to 1.5-fold change (bright red). The dendrogram on the
right indicates the order of the sample grouping, with more similar
samples being grouped together ﬁrst. The color band on the left
shows the genders of the samples, with red for females, and blue
for males.
other, as evidenced by the succession of self-similar bands
of three rows (highlighted by the yellow lines in Figure 4).
The clustering also shows a general trend of clustering
the samples based on gender appeared (highlighted by
the blue and red bars for males and females, resp., in
Figure 4).
3.7. Gender Eﬀects. In addition to the results seen in the
hierarchical clustering (Figure 4), after ﬁtting the mixed-
eﬀects model to the residuals from the SLA at the spots
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Figure 5: Expression data for alpha-2-HS-glycoprotein, with an
average increase of 1.49-fold between the female and male groups,
and FDR-adjusted gender-eﬀect P-value =.055. The samples are in
SubjectNumberTimeformat,whereSubjectNumberrangesfrom01
to 11, and the Time values {x, y,a n dz } correspond to {T1, T2,
and T3}. The annotations indicate the gels (numbers) and the dyes
(red for Cy5, green for Cy3) corresponding to the samples. Dotted
lines connect samples multiplexed on the same gel. Crosses indicate
sampleaveragesoverthetechnicalreplicates.Thesolidlineconnects
all sample averages. Boxes around the three Time values for each
SubjectNumber highlight male and female genders (blue and red
respectively) added for illustrative purposes only.
matchedon75%ofthegels,17spotsshowedgender-eﬀectP-
value <.01. None of these spots were found to be signiﬁcant
(P-value <.01) after the False Discovery Rate (FDR) method
[41] for multiple comparisons was applied suggesting that
larger numbers of samples are needed to validate gender
diﬀerences in the human plasma proteome. Despite the
lack of statistically signiﬁcant data on gender diﬀerences,
trends in this dataset suggest that future, larger datasets
might enable the diﬀerentiation of protein expression levels
due to gender. One spot, 1659, had FDR-adjusted gender-
eﬀect P-value equal to.055 with a 1.49-fold-change between
the male and female groups (Figure 5). Five additional
spots (466, 1626 alpha-2-HS-glycoprotein, 1650 alpha-2-
HS-glycoprotein, 1652 alpha-2-HS-glycoprotein, 1678) had
adjusted P-values of.11. The results were similar when ﬁtting
the same model to the residuals from the statistically nor-
malized SLA, albeit with P-values that slightly exceeded their
corresponding values based on the SLA. Three of the spots
exhibiting gender eﬀects were identiﬁed as alpha-2-HS-
glycoprotein, which has been shown to vary between males
and females. The concentration of alpha-2-HS-glycoprotein
has been found to undergo a progressive age-related
decrease in women, while men show no noticeable change
[36].
T h er e m o v a lo ft h ed y ea n dg e le ﬀects using the model
in (1) proved to be a beneﬁcial preprocessing step. Without
this step, when the mixed-eﬀect model was ﬁt to the
original SLA, the smallest FDR-adjusted gender-eﬀect P-
value was.19 (spot 1659). When the same model was ﬁt to
the statistically normalized SLA, the smallest FDR-adjusted
P-valuewasalso.19(spot1659).Thestatisticalnormalization
improved the quality of the data slightly, but it did not
reduce dramatically the observed P-values. On the other10 Journal of Biomedicine and Biotechnology
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Figure 6: Hierarchical clustering of the 33 samples (x-axis) based on the abundance of the 78-identiﬁed protein spots on the y-axis, using
Euclidean distance metrics and average linkage methods. The samples are in SubjectNumberTime format, where SubjectNumber ranges
from 01 to 11, and the Time values (x, y,a n dz) correspond to (T1, T2,a n dT3). The intensities range from −1.5 (bright green) to 1.5 (bright
red). The dendrogram on the top indicates the order of the sample grouping, with samples corresponding to the lower leaves being grouped
together ﬁrst. Similarly, the dendrogram on the left indicates the ordering of the protein spots. All transferrin (TF) and vitamin D-binding
protein (GC) identiﬁcations are highlighted in blue and red, respectively.
hand, pooling the information across the gels to remove
the common dye and gel eﬀects strengthened the signal and
reduced markedly the FDR-adjusted P-values. As explained
in the previous paragraph, for spot 1659, the new P-value
was close to.05.
3.8. Multivariate Analysis of Identiﬁed Proteins. Hierarchical
clusteringoftheidentiﬁedproteins(Figure 6)wasc onduct ed
using the Euclidean distance metric and average linkage
methods. For all subjects, other than subject 10, the ﬁrst
clustering step placed the three samples of that subject into
one cluster. Subject 10 had two time points grouped together
(x and z) with the third point (y) separated by Subject 3.
Because the 78 identiﬁed proteins were the most diﬀerential
between time and subjects, it is not unexpected to see
clustering results that may not perfectly align all subjects
or time points. For example, all protein spots identiﬁed
as transferrin (TF) clustered together due to their similar
expression patterns, while the vitamin D-binding protein
(GC) spots were found in multiple clusters due to diﬀerences
in expression patterns between the individuals. Multiple
proteinsmayclustertogetherduetocoregulationandsimilar
functions, and in the case of APOA4 and APOA1 (Figure 6),
coregulation has been reported [37, 42].
4. Conclusion
Statistical analysis of a 2-D DIGE experiment involving
triplicate plasma samples from eleven human subjects takenJournal of Biomedicine and Biotechnology 11
at three time points separated by several weeks demonstrated
that the subject-to-subject variation exceeded the time-
within-subject variation. The variation in the human plasma
proteome reported here was greater than a previous technical
variation study wherein one plasma sample was processed
multiple times [13].
Here, for 70% of the high-quality protein spots, the
coeﬃcient of variation of the SLA was less than 30% across
all subjects and time points, thus indicating that the baseline
expression levels of those proteins are relatively stable in the
population represented by the subjects in this study. Only 21
spots had larger than 50% CV, suggesting that these protein
isoforms should be avoided as biomarker candidates. Many
of these protein spots represent medium to high abundance
plasmaproteins.Sincetheyarehigherabundance,theymight
bias LC/MS datasets, but since the total number of these
spots relative to the total plasma proteome is small, their
total inﬂuence on a sample is likely also small. In addition,
protein spots with gender-related diﬀerences should be
considered separately for males and females. However, more
thorough studies, including the use of a larger population
set with additional time points over longer periods of
time, are recommended to more fully address individual,
longitudinal, and gender variability as related to biomarker
discovery.
We noted that preprocessing the data by ﬁrst removing
the ﬁxed eﬀects of the gels and dyes was important in data
analysis and improved the quality of the data. This step
resulted in six protein spots showing a statistically signiﬁcant
gender eﬀect at an FDR-adjusted 11% signiﬁcance level.
Without the preprocessing step, the smallest gender eﬀect P-
value was.19. While removing the gel and dye eﬀects lead to
stronger conclusions, the additional statistical normalization
of the SLA had only marginal eﬀects and did not alter the
conclusions.
Spot matching confounds gel- and software-related pro-
tein diﬀerences with real biological eﬀects. In the present
study, we only considered spots that were matched on at
least 75% of the gels. Spots with lower matching quality
can be investigated separately, as they may correspond to
proteins that are absent or have very low expression in
certain individuals, but which may have biological signif-
icance. We envision that such studies will become more
relevant as the ﬁeld of personalized medicine matures,
and as detection and matching algorithms continue to im-
prove.
This study represents a ﬁrst step toward quantitating
the longitudinal and individual variation in the human
plasma proteome, as measured on the 2-D DIGE platform.
Interestingly, gender-related variations were also detected
suggesting that gender variability should also be considered
in biomarker discovery. Future, larger-scale experiments that
include more subjects representative of various population
segments, encompassing diﬀerences in ethnicity, age, gender,
disease status, and other relevant factors, have the potential
to deﬁne baseline proteomic similarities and diﬀerences in
thehumanpopulation,whichwillinturnfacilitateimproved
biomarker discovery.
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